The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 3, 2003, Pages 749-754

  Potters, Louis ^a   Purrazzella, Rosemary ^b   Brustein, Sheryl ^b   Fearn, Paul ^a   Huang, David ^a   Leibel, Steven A ^a   Kattan, Michael W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Mercy Medical Center   (United States)

Author keywords

Brachytherapy; Gleason score; Modeling; Pathology; Prostate neoplasm; Radiotherapy

Indexed keywords

IMPLANTS (SURGICAL); REGRESSION ANALYSIS; TUMORS; ULTRASONIC IMAGING;

BEAM RADIATIONS;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; BEAM THERAPY; BIOCHEMISTRY; CALCULATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOLLOW UP; HAZARD; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RANK SUM TEST; RECURRENT DISEASE; REGRESSION ANALYSIS; RELAPSE;

EID: 0038281332     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00009-9     Document Type: Article

References (19)

1. Grimm P.D., Blasko J.C., Sylvester J.E., Meier R.M., Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 51:(1):2001;31-40.
2. Nag S., Beyer D., Friedland J., Grimm P., Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:(4):1999;789-799.
3. Prestidge B.R., Prete J.J., Buchholz T.A., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 40:(2):1998;461-465.
4. D'Amico A.V., Renshaw A.A., Schultz D., Rocha S., Richie J.P. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA< or = 10 ng/ml and T1c,2a Implications for patient selection for prostate-only therapy . Int J Radiat Oncol Biol Phys. 45:(4):1999;847-851.
5. Fleming I., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual. Fifth edition: 1997;203-208 Lippincott-Raven, Philadelphia.
6. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:(2):1999;391-395.
7. Beyer D., Nath R., Butler W., et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. Int J Radiat Oncol Biol Phys. 47:(2):2000;273-275.
8. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine [see comments] [published erratum appears in Med Phys 1996 Sep;23(9):1579]. Med Phys 1995;22(2):209-234.
9. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37(5):1035-1041.
10. Kattan M.W., Fearn P.A., Leibel S., Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 48:(5):2000;1469-1474.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol. 53:1958;457-616.
12. Cox D.R., Abadir R. Regression models and life tables. J R Stat Soc. 34:(Series B):1972;187-220.
13. Herman C.M., Kattan M.W., Ohori M., Scardino P.T., Wheeler T.M. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer A multivariate analysis of 823 men treated with radical prostatectomy . Am J Surg Pathol. 25:(5):2001;657-660.
14. Potters L., Purrazzella R., Brustein S., Fearn P., Leibel S.A., Kattan M.W. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer. 95:(7):2002;1451-1456.
15. Ross P.L., Scardino P.T., Kattan M.W. A catalog of prostate cancer nomograms. J Urol. 165:(5):2001;1562-1568.
16. Potters L, Cha C, Ashley R, et al. The role of external beam irradiation in patients undergoing prostate brachytherapy. Urol Oncol 2000;5:112-117.
17. Blasko J.C., Grimm P.D., Sylsvester J.E., Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 57:(3):2000;273-278.
18. Ragde H., Korb L.J., Elgamal A.A., Grado G.L., Nadir B.S. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 89:(1):2000;135-141.
19. Potters L., Fearn P., Kattan M.W. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy. 1:2002;36.